Expres2ion Biotech Holding AB
1 Jun - 31 Aug 2020Exercising of warrants
Expres2ion Biotech Holding AB has developed a platform, Expres2, for fast pre clinical and clinical development and solid production of complex proteins for new vaccnies and diagnoses. Expres2 is regulatory validated to be clinically provided.
The patented ExpreS2 protein expression system is built for optimal discovery, preclinical development and GMP production of hard-to-express proteins used in vaccines and vaccine-like treatments.
The system is built upon non-viral fruit fly cells and has the ability to quickly establish stable polyclonal pools that provide high protein expression levels. Introduction of the protein to express in the system is conducted through the use of vector DNA containing a constitutive proprietary hybrid promoter.
Read more on the company's website
The offer in summary
Assignment: Exercising of staff warrants
Subscription period: 1 June - 31 August 2020
